Journal of Research in Pharmacy, cilt.23, sa.5, ss.952-959, 2019 (Hakemli Dergi)
Histone deacetylases (HDAC) are evolutionary conserved enzymes, which catalyze removal of acetyl
groups from histone and non-histone proteins, therefore, control multiple biological processes. Inhibition of their
activities have been investigated to modify gene expression and/or protein functions not only for treatment of certain
diseases but also for understanding functions of deacetylase isoforms. We previously synthesized aryl butenoic acid
derivatives and identified their pan-HDAC inhibition activities. In this study, we investigated selective inhibition
activities of these derivatives (C1, C3, C4) on class I HDACs using in silico and in vitro approaches. Molecular docking
studies of the three aryl butenoic acid derivatives were performed on the crystal structures of HDAC 1, 2, 3 and 8, which
were obtained from RCSB protein databank, using Glide software. In vitro inhibition activities of the compounds at two
different concentrations were tested using fluorometric assay. In silico results indicated that all the compounds showed
higher affinity to HDAC 1 and 8 than other class I deacetylases. In vitro analysis showed that the compounds inhibit
HDAC 8 more effectively than HDAC 1. It was shown that C1 had higher binding affinity and inhibition activity to both
enzymes. We concluded that, C1 inhibited both HDAC 1 and 8, however, C3 and C4 showed slight selectivity for HDAC
8 over HDAC 1, which was in agreement with the docking studies. Further cell culture studies will be valuable to
determine increased acetylation on target proteins in response to compound treatment.